Shah, V.; McNatty, A.; Simpson, L.; Ofori, H.; Raheem, F.
Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy. Biomedicines 2023, 11, 950.
https://doi.org/10.3390/biomedicines11030950
AMA Style
Shah V, McNatty A, Simpson L, Ofori H, Raheem F.
Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy. Biomedicines. 2023; 11(3):950.
https://doi.org/10.3390/biomedicines11030950
Chicago/Turabian Style
Shah, Vishal, Andrea McNatty, Lacey Simpson, Henry Ofori, and Farah Raheem.
2023. "Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy" Biomedicines 11, no. 3: 950.
https://doi.org/10.3390/biomedicines11030950
APA Style
Shah, V., McNatty, A., Simpson, L., Ofori, H., & Raheem, F.
(2023). Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy. Biomedicines, 11(3), 950.
https://doi.org/10.3390/biomedicines11030950